Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Outstanding (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Shares Outstanding for 16 consecutive years, with $138.1 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Shares Outstanding rose 11.2% year-over-year to $138.1 million, compared with a TTM value of $138.1 million through Jun 2025, up 11.2%, and an annual FY2024 reading of $124.4 million, up 15.9% over the prior year.
  • Shares Outstanding was $138.1 million for Q2 2025 at Arrowhead Pharmaceuticals, up from $124.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $138.1 million in Q2 2025 and bottomed at $104.0 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $112.1 million, with a median of $106.9 million recorded in 2023.
  • The sharpest move saw Shares Outstanding increased 1.1% in 2023, then grew 16.15% in 2024.
  • Year by year, Shares Outstanding stood at $104.8 million in 2021, then rose by 1.28% to $106.1 million in 2022, then increased by 1.28% to $107.5 million in 2023, then rose by 15.96% to $124.7 million in 2024, then grew by 10.82% to $138.1 million in 2025.
  • Business Quant data shows Shares Outstanding for ARWR at $138.1 million in Q2 2025, $138.1 million in Q1 2025, and $124.7 million in Q4 2024.